Dishman Carbogen Amcis Limited announced that its Board of Directors has approved the audited financial results for the quarter and year ended March 31, 2026. The meeting, held on May 19, 2026, also sanctioned key corporate actions including the re-appointment of statutory auditors and a revision to external commercial borrowing limits.

Financial Results and Auditor Appointment

The Board approved the Standalone and Consolidated Audited Financial Results for the fourth quarter and fiscal year 2026. The audit report, issued by M/s. T R Chadha & Co. LLP, Chartered Accountants, carries an unmodified opinion. Additionally, the Board recommended the re-appointment of M/s. T R Chadha & Co. LLP as Statutory Auditors for a second term of five consecutive years, subject to shareholder approval at the upcoming Annual General Meeting.

External Commercial Borrowings

In a strategic move to refinance existing debt, the Board approved raising External Commercial Borrowings (ECB) up to CHF 200 million from promoter group company Aamanya AG. This revises the earlier proposed limit of CHF 135 million. The loan, which is unsecured, carries an interest rate of SARON + 400 bps (currently 4% p.a.) and has a tenor of 10 years. The funds will be utilized to refinance existing rupee debt, meet working capital and capital expenditure requirements, and for other permitted purposes.

Borrowing Limits and Shareholder Approval

Consequent to the ECB approval, the Board passed a resolution to increase the borrowing limits under Section 180(1)(c) of the Companies Act, 2013 from Rs. 1,700 crores to Rs. 4,000 Crores. This increase is subject to shareholder approval. The company will seek the requisite consent for both the ECB and the increased borrowing limits through an Extra-Ordinary General Meeting (EGM), the date for which will be communicated later.

Key ECB Details

Dishman Carbogen Amcis Limited announced on 5 May 2026 that its wholly-owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has successfully completed an unannounced Good Manufacturing Practice (GMP) inspection by China's National Medical Products Administration (NMPA) at its Shanghai facility. The disclosure was made under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Inspection Overview

The unannounced inspection was conducted on 14 April 2026 and encompassed a comprehensive on-site assessment of the Shanghai facility's operations. Key details of the inspection are summarised below:

The inspection covered the following areas:

• API manufacturing processes and operations
• Quality control laboratories
• Documentation practices
• Overall quality management systems
• Site's Quality System readiness

The inspection concluded without observations, and no issues requiring formal explanation were identified. Recommendations were provided to support ongoing continuous improvement.

Leadership Remarks

Senior officials from CARBOGEN AMCIS commented on the significance of the outcome.

Stephanie Schlienger, V.P. Quality & Compliance of CARBOGEN AMCIS, stated: "This outcome reflects the high level of preparedness and expertise demonstrated by our Shanghai team, as well as the strength and maturity of our Quality System. The successful completion of an unannounced inspection with no observations underlines our commitment to maintaining the highest GMP standards across all aspects of our operations."

Simone Maggi, Site Quality Head of CARBOGEN AMCIS Shanghai, noted: "For the Shanghai site, the significance of this inspection lies in the fact that it was unannounced. Such inspections test the system as it operates in routine conditions, and this result confirms both the consistency of GMP execution across the site and the readiness and competence of our team."

Stephan Fritschi, CEO of CARBOGEN AMCIS, added: "Successfully completing an unannounced NMPA inspection with no observations is a significant achievement and a strong validation of our global quality culture. It demonstrates our ability to consistently meet rigorous regulatory expectations and reinforces confidence in our Shanghai site as a reliable partner for our customers worldwide."

Role of the Shanghai Facility

The Shanghai facility plays a key role within CARBOGEN AMCIS' global network, supporting API manufacturing and process development activities. The site's successful inspection outcome acknowledges its capability to deliver high-quality services in line with international regulatory requirements. CARBOGEN AMCIS is a leading service provider offering drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Dishman Carbogen Amcis Limited, headquartered in Ahmedabad, India, is a global outsourcing partner for the pharmaceutical industry, with operations across Europe, China, and India.